- Home
- Companies
- latin america
- antigen presentation
Refine by
Locations
- Latin America
- Antigua & Barbuda
- Argentina
- Aruba
- Bahamas
- Barbados
- Belize
- Bolivia
- Brazil
- Cayman Islands
- Chile
- Colombia
- Costa Rica
- Cuba
- Dominica
- Dominican Republic
- Ecuador
- El Salvador
- Grenada
- Guatemala
- Guyana
- Haiti
- Honduras
- Jamaica
- Mexico
- Netherlands Antilles
- Nicaragua
- Panama
- Paraguay
- Peru
- Puerto Rico
- St. Kitts & Nevis
- St. Lucia
- St. Vincent & The Grenadines
- Suriname
- Trinidad
- Uruguay
- Venezuela
Antigen Presentation Suppliers Serving Latin America
38 companies found
based inIrving, TEXAS (USA)
Optimum Therapeutic Solutions is a visionary leader in nutrient and supplement solutions. Recognizing a need for a line of nutritional supplements designed by health care professionals, for health care professionals, Optimum Therapeutic Solutions ...
S-Acetyl Glutathione is an acetylated form of glutathione. This form is well-absorbed and more stable throughout the digestive tract than other forms on the market. Use of stomach acid-resistant capsules further protect stability. Laboratory data ...
based inLublin, POLAND
We are a Polish biotechnology company with long manufacturing traditions. We have been present on the Polish and international markets since 1944. We are challenged and truly honoured to provide the leading, innovative medical solutions, and, due to ...
Name of the Medicinal Product Gamma anty-D 50, 50 micrograms/ml Solution for injection. Qualitative and Quantitative Composition: 1 ml of the solution consists of: Human anti-D immunoglobulin 50 micrograms (250 IU) . Human protein content not less ...
based inEpalinges, SWITZERLAND
AC BioScience Ltd., a clinical-stage biotech company and a developer of immune modulating and angiogenic cancer therapies. AC BioScience LTD. is a Swiss biotech company, pioneering the development of novel therapies in immuno-oncology and tumor ...
Our patented Beta-carboline derivative (ACB1801) is an actin dynamic modulator which induces cellular F-actin network remodeling (tumor reversal); this in turn translates into immuno-competency that allows the immune system to recognize tumor cells ...
based inHolliston, MASSACHUSETTS (USA)
BTX has been at the forefront of electroporation technology since we introduced the first commercially available electroporator in 1983. For over 30 years, we have made it our priority to focus only on electroporation and electrofusion. This focus ...
The AgilePulse In Vivo System, used for animal immunization, vaccine development, and gene therapy, provides an intra-muscular, intra-dermal, or intra-tumor electroporation solution to produce maximum transfection efficiency. Traditional in vivo ...
based inSeoul, SOUTH KOREA
GI Innovation is a bio-venture company that researches and develops innovative protein new drugs through well-structured translational research. The primary research and development for GI Innovation is immuno-oncology drug and allergy disease and ...
Promotes the generation of cancer-specific effector T cell (Teff) in lymph nodes, and induces the activation and proliferation of tumor-infiltrating Teff and NK cells. Controls the immuno-suppressive function of regulatory T cells (Tregs) in tumor ...
based inMainz, GERMANY
Fuelled by Innovation: With a pioneering spirit and high technical expertise, ORGENTEC has become firmly established in medical diagnostics. Our employees’ talent and skills establish the basis for our success. At our headquarters in Mainz, Germany, ...
Anti-DGP IgA is an ELISA-based, automated, in-vitro test system for the quantitative determination of IgA antibodies against deamidated gliadin protein epitopes (DGP) in human serum or plasma. These assays are used to support a diagnosis of celiac ...
based inNiel, BELGIUM
eTheRNA has developed a proprietary and integrated set of platform technologies that are overcoming the challenges facing the development of next generation mRNA therapeutics. Our platform includes mRNA construct design and optimization, proprietary ...
Our mRNA platforms and vast in-house experience help partners quickly optimize, screen and select an mRNA code, develop a candidate, and ensure effective & prime manufacturing of the mRNA from research grade to GMP scale. Our platform’s ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and ...
based inVienna, AUSTRIA
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our non-replicating and ...
The immune system is the body’s natural defense mechanism against pathogens. Our proprietary technology is capable of targeting and treating disease with a tailored immune response. Our science is based on a novel and highly differentiated ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Vandetanib hydrochloride (D6474 hydrochloride) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib hydrochloride also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and ...
based in, CALIFORNIA (USA)
AIVITA Biomedical is a biotechnology company developing personalized vaccines that target COVID-19 and the seed of all cancers using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity ...
based inRehovot, ISRAEL
ProSpec is an evolving biotech company providing highly purified proteins worldwide which serve the research community with cytokine-related products for cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem ...
4 1BBL Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 184 amino acids and having a molecular mass of 19.5kDa. The 4 1BBL is purified by proprietary chromatographic techniques. ...
based inEdmonton, ALBERTA (CANADA)
Akshaya Bio Inc. (Akshaya) is a privately held development stage biotechnology company located in Edmonton, Alberta, Canada. Akshaya develops innovative therapeutics for infectious diseases and cancer. Akshaya's proprietary Chimigen® Platform ...
The Chimigen® Platform is a flexible platform vaccine technology designed to elicit both humoral and cellular immune responses in ...
based inOxford, UNITED KINGDOM
ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen ...
Pro5® MHC Class I Pentamers the most consistent, most published commercial technology for detecting antigen-specific CD8+ T cells. Pro5® MHC Pentamer. The beautiful rational design of Pro5® MHC Pentamers ...
based inChatham, NEW JERSEY (USA)
Tonix is a clinical-stage biopharmaceutical company focused on developing novel therapies and vaccines to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. At Tonix, we are focused on ...
TNX-1850 is the planned new version of the TNX-1800 vaccine that encodes spike protein from SARS-CoV-2 BA.2 ...
based inHouston, TEXAS (USA)
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical company based in the Houston, TX area that is developing GP2, a novel peptide immunotherapy, and has commenced a Phase III clinical trial, called Flamingo-01. GP2 is derived ...
Cancer Immunotherapies are a New Method of Cancer Treatment. Among the more established treatment options, such as surgery, chemotherapy, targeted therapy, and radiation therapy, cancer immunotherapy is a rapidly emerging and important field. It ...
based inSeattle, WASHINGTON (USA)
Universal Cells is a Seattle-based company that is producing engineered stem cell lines that can avoid rejection and be used in allogeneic cell therapy treatments for the people who need them. One Cell, Many Therapies. Universal Cells edits genes ...
The HLA Class II molecules DP, DQ and DR present peptides to CD4+ T cells and are composed of polymorphic alpha and beta chains. All Class II molecules are expressed from promoters that require the same set of transcription factors. Mutations in ...
based inWayne, PENNSYLVANIA (USA)
Sino Biological is committed to providing high-quality recombinant protein and antibody reagents and to being a one-stop technical services shop for life science researchers around the world. All of our products are independently developed and ...
FCAR, also called FcαRI or CD89, is a type I transmembrane receptor for Fc region of IgA which is the most abundant immunoglobulin in mucosal areas but is only the second most common antibody isotype in serum. This receptor is present on the ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
The injectable modality (AIM INJ) is an injectable pharmaceutical product of AIM nanoparticles decorated with antigen-specific peptides and co-stimulatory molecules appropriate for the disease being targeted. Based on specific size and ...